SNV-201
Alzheimer's Disease & Neurodegeneration
Restoring brain bioenergetic capacity via pharmaceutical-grade ketone delivery. Informed by 103 preclinical studies demonstrating 60% average cognitive improvement, multiple human RCTs, and Cochrane-level evidence across the ketone-cognition axis.
Therapeutic rationale
The Alzheimer's brain is in an energy crisis.
FDG-PET imaging reveals cerebral glucose hypometabolism 20+ years before Alzheimer's symptoms (Reiman et al., PNAS 2004). By the time of clinical diagnosis, brain glucose uptake is reduced to 75–90% of normal. This is not a consequence of neurodegeneration. The metabolic deficit precedes and predicts cognitive decline.
Critically, dual-tracer PET studies (Cunnane et al., 2016) demonstrate that while glucose uptake is severely impaired, ketone uptake remains at approximately 100% of normal. The brain retains full capacity to oxidize an alternative fuel. The machinery is intact. The substrate is absent.
Anti-amyloid therapies have demonstrated that clearing the pathological hallmark does not restore function. Amyloid is removed, but neurons continue to die. The dissociation between target engagement and clinical benefit is consistent with a bioenergetic deficit that exists upstream of, and independently from, amyloid accumulation.
SNV-201 addresses this deficit directly: an oral prodrug designed to achieve sustained, therapeutic-level brain ketone availability without dietary restriction, bypassing the impaired glucose pathway through an alternative fuel that the AD brain can still fully utilize.
Clinical evidence
Human data: RCTs, meta-analyses, and biomarker studies.
The ketone-cognition axis is supported by randomized controlled trials, dose-response data, and imaging biomarkers.
Bonnechère et al., 2025 (Meta-analysis)
18 studies, n=875. Standardized mean difference (SMD) = 0.26 for cognitive improvement with ketone-elevating interventions across Alzheimer’s and MCI populations. Consistent positive signal across heterogeneous study designs.
Henderson et al., 2009 (RCT, n=152)
+4.77-point improvement on ADAS-Cog in APOE4-negative cohort. APOE4-positive patients showed near-zero response, establishing metabolic genotype as a stratification variable. The divergence is consistent with differential ketone utilization capacity.
Krikorian et al., 2012 (n=23, MCI)
Dose-response correlation r=0.45 between blood ketone levels and secondary memory performance. Higher ketone exposure produced proportionally larger cognitive gains, establishing a pharmacologically targetable dose-response relationship.
Cunnane et al., 2016 (FDG-PET/11C-AcAc-PET)
Brain glucose uptake reduced to 75–90% of normal in AD, but ketone uptake preserved at approximately 100%. The brain retains full capacity to oxidize ketones even as glucose metabolism fails. This is the bioenergetic bypass that ketone therapeutics exploit.
Reiman et al., PNAS 2004
Cerebral glucose hypometabolism detectable on FDG-PET 20+ years before symptom onset in APOE4 carriers. The metabolic deficit is not a consequence of neurodegeneration. It precedes and potentially drives it.
Preclinical corpus
103 studies. 60% average cognitive improvement.
Across APP/PS1, 3xTg-AD, 5xFAD, and aging models, ketone-elevating interventions consistently improve cognition, reduce pathology, and restore synaptic function.
Mechanism of action
Six validated pathways. One metabolic intervention.
SNV-201 engages multiple neuroprotective mechanisms simultaneously through sustained ketone body elevation. Each pathway is independently validated in the published literature.
NLRP3 inflammasome blockade
BHB directly inhibits NLRP3 inflammasome assembly, reducing IL-1β and IL-18 release. This addresses the neuroinflammatory cascade that accelerates neuronal loss independently of amyloid pathology.
Youm et al., Nature Medicine 2015
Long-term potentiation (LTP) restoration
Ketone metabolism restores synaptic plasticity by normalizing NAD+/NADH ratios and enhancing mitochondrial ATP output at the synapse. LTP is the cellular correlate of memory formation.
Multiple preclinical studies (APP/PS1, 5xFAD)
Microglial phenotype modulation
BHB shifts microglia from the pro-inflammatory M1 phenotype to the neuroprotective M2 phenotype via HDAC inhibition and GPR109A signaling, reducing chronic neuroinflammation while preserving phagocytic clearance.
Huang et al., 2018; Shippy et al., 2020
NAD+ regeneration
Ketone oxidation regenerates NAD+ through the electron transport chain, restoring the NAD+/NADH ratio that is depleted in AD. NAD+ is required for sirtuin activation, DNA repair, and mitochondrial biogenesis.
Verdin, 2015; Xie et al., 2020
Autophagy activation
BHB activates autophagy through AMPK signaling and mTOR inhibition, enhancing clearance of misfolded proteins, damaged mitochondria, and other cellular debris that accumulates in neurodegeneration.
Camberos-Luna & Massieu, 2020
Epigenetic regulation via HDAC inhibition
BHB is an endogenous Class I HDAC inhibitor, upregulating FOXO3a and MT2 (oxidative stress resistance), BDNF (neurotrophin support), and mitochondrial biogenesis genes.
Shimazu et al., Science 2013
The exposure gap
Why prior approaches produced modest effects.
The dose-response data (Krikorian r=0.45) predicts that larger, more sustained ketone exposures should produce proportionally larger cognitive benefits. Existing approaches achieve only a fraction of the target exposure.
Patient stratification
APOE4 genotype as a response predictor.
The Henderson 2009 RCT revealed a clear genotype-response interaction: APOE4-negative patients showed +4.77 ADAS-Cog improvement, while APOE4-positive patients showed near-zero response. This is not a failure of the mechanism. It reflects differential ketone utilization capacity linked to APOE genotype.
APOE4 carriers represent approximately 25% of the general population and 65–80% of AD clinical trial populations. By stratifying on metabolic genotype, SNV-201 can enrich for responders and demonstrate a clear treatment effect in the population most likely to benefit.
This stratification also explains the modest overall effect sizes in prior ketone trials: when responders and non-responders are analyzed together, the signal is diluted. Enrichment for APOE4-negative patients should produce a substantially larger treatment effect.
Development pathway
505(b)(2) regulatory strategy.
SNV-201 leverages the 505(b)(2) regulatory pathway, referencing the established safety and biology of endogenous ketone bodies. Precedent: Dojolvi (triheptanoin), FDA-approved for long-chain fatty acid oxidation disorders via the same pathway.
Clinical development proceeds through PK/safety (healthy volunteers), proof-of-concept in MCI/mild AD with ADAS-Cog as primary endpoint, and biomarker-enriched Phase 2 studies with APOE4 stratification and FDG-PET metabolic endpoints.